A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
Not yet recruiting · NCT07510594 · Registry updated 2026-04-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC | Extrapulmonary Neuroendocrine Carcinoma; Large-Cell Neuroendocrine Carcinoma of the Lung | Not yet recruiting | Phase 2 | 2026-04-03 | NCT07510594 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 287 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tianjin Medical University Cancer Institute & Hospital | Tianjin | China | 23 |